Hunan Er-Kang Pharmaceutical Co 300267.SZ · CNY

Its shares trade on Shenzhen under the ticker 300267.SZ. It has been listed since 27 September 2011. In the fiscal year to 31 December 2025, it reported revenue of CN¥1.17bn and a net loss of CN¥379.8m. At that date it held total assets of CN¥4.86bn and shareholders' equity of CN¥4.03bn.

Hunan Er-Kang Pharmaceutical Co., Ltd. engages in the research and development, production and sale of pharmaceutical products. The company is headquartered in Changsha, Hunan. The company went IPO on 2011-09-27. The Company’s pharmaceutical excipients mainly consist of glycerol for medicine, sugar for medicine, ethanol for medicine, propylene glycol for medicine, as well as sodium hydroxide for medicine and others. Its bulk drugs consist of sulfadiazine, sulphaguanidine and resorcinol, among others. Its finished drugs consist of sulbenicillin sodium injections and compound liquorice tablets. The firm distributes its products in domestic market and to overseas markets.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Fangwen ShuaiChairman of the Board, since 2010CN¥512,900
• Ms. Xun ZhaoChief Financial Officer, Director, since 2018CN¥389,800
• Mr. Qingrong SunGeneral Manager, Director, since 2019CN¥1.0m
• Mr. Jishun GuDeputy General Manager, Secretary of the BoardCN¥514,800
• Ms. Xiangyan ShiDeputy General Manager, Director, since 2018CN¥535,300
• Mr. Hui WangDeputy General ManagerCN¥405,100
• Mr. Licheng ZhangDeputy General Manager, since 2019CN¥396,200
• Mr. Jiang XiaoChief EngineerCN¥465,800
• Mr. Wuzhen JiangIndependent DirectorCN¥150,000
• Mr. Xue TanIndependent DirectorCN¥150,000
• Mr. Junwen WangIndependent DirectorCN¥150,000

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.